Bruker (NASDAQ:BRKR) Releases FY 2025 Earnings Guidance

Bruker (NASDAQ:BRKR) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided EPS guidance of 2.670-2.720 for the period, compared to the consensus EPS estimate of 2.680. The company issued revenue guidance of $3.5 billion-$3.5 billion, compared to the consensus revenue estimate of $3.6 billion.

Wall Street Analyst Weigh In

BRKR has been the topic of several recent research reports. TD Cowen dropped their target price on shares of Bruker from $72.00 to $70.00 and set a “hold” rating on the stock in a report on Wednesday, November 6th. Barclays dropped their price objective on shares of Bruker from $69.00 to $65.00 and set an “overweight” rating on the stock in a research note on Monday. Wells Fargo & Company reduced their price objective on shares of Bruker from $78.00 to $75.00 and set an “overweight” rating for the company in a research note on Wednesday, November 6th. The Goldman Sachs Group raised Bruker from a “sell” rating to a “neutral” rating and set a $60.00 target price on the stock in a research report on Thursday, December 5th. Finally, Citigroup reduced their price target on Bruker from $80.00 to $75.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Six analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $74.09.

Bruker Stock Down 2.0 %

Shares of Bruker stock traded down $1.01 on Thursday, reaching $50.64. The stock had a trading volume of 1,827,096 shares, compared to its average volume of 1,566,893. The company has a 50 day moving average price of $57.88 and a 200 day moving average price of $60.77. The company has a quick ratio of 0.73, a current ratio of 1.66 and a debt-to-equity ratio of 1.24. Bruker has a 1 year low of $48.07 and a 1 year high of $94.86. The stock has a market capitalization of $7.68 billion, a P/E ratio of 24.35, a P/E/G ratio of 3.81 and a beta of 1.16.

Bruker (NASDAQ:BRKR) last issued its quarterly earnings data on Thursday, February 13th. The medical research company reported $0.76 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.75 by $0.01. Bruker had a net margin of 9.41% and a return on equity of 21.52%. As a group, equities research analysts forecast that Bruker will post 2.4 EPS for the current year.

Insiders Place Their Bets

In related news, CEO Frank H. Laukien bought 100,000 shares of the company’s stock in a transaction on Monday, November 18th. The shares were bought at an average price of $50.14 per share, with a total value of $5,014,000.00. Following the transaction, the chief executive officer now owns 38,439,563 shares in the company, valued at approximately $1,927,359,688.82. This trade represents a 0.26 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 28.30% of the stock is owned by insiders.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.